Evidence map›Paper›PMID 31848903›Full record

ArticleGeneral thoracic and cardiovascular surgery2020

The impact of perioperative heparin bridging therapy in lung cancer surgery.

Masataka Mori, Yoshinobu Ichiki, Masatoshi Kanayama, Akihiro Taira, Shinji Shinohara, Taiji Kuwata, Naoko Imanishi, Kazue Yoneda, Koji Kuroda, Fumihiro Tanaka

Abstract read
PubMed Publisher
In one paragraph

Article in General thoracic and cardiovascular surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Masataka MoriSecond Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan. masataka-m@med.uoeh-u.ac.jp.ORCID http://orcid.org/0000-0002-1473-8669
Yoshinobu IchikiDepartment of General Thoracic Surgery, National Hospital Organization Saitama Hospital, Wako, Japan.
Masatoshi KanayamaSecond Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan.
Akihiro TairaSecond Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan.
Shinji ShinoharaSecond Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan.
Taiji KuwataSecond Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan.
Naoko ImanishiSecond Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan.
Kazue YonedaSecond Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan.
Koji KurodaSecond Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan.
Fumihiro TanakaSecond Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe impact of perioperative heparin bridging (HB) for lung surgery in patients on anti-clotting drugs remains unclear. We performed a retrospective study to assess its effect on surgical safety by comparing HB and non-HB groups.

methodsThis study included 274 consecutive patients on anti-clotting drugs who underwent surgery for lung cancer. Of these, 77 received HB and 197 did not. Propensity score matching extracted 124 patients, consisting of 62 patients with HB and 62 patients without HB. Endpoints were surgical safety.

resultsThere was no statistically significant difference in the outcomes of surgical safety outcomes between the HB and non-HB group after propensity-score matching, operative time (172 vs. 203 min, p = 0.131), volume of blood loss (60 vs. 70 ml, p = 0.335), need for intraoperative RBC transfusion (3.2 vs. 6.5%, p = 0.680), chest tube drainage volume on the 1st postoperative day (200 vs. 200 ml, p = 0.796), and chest tube placement duration (3 vs. 3 days, p = 0.606).

conclusionsThe influence of perioperative HB on postoperative thromboembolic or bleeding events in lung cancer surgery is not obvious, but its surgical safety appears to be acceptable.

Indexed as

AgedAged, 80 and overAnticoagulantsBlood Loss, SurgicalBlood TransfusionBlood VolumeChest TubesDrainageFemaleHeparinHumansLung NeoplasmsMaleMiddle AgedOperative TimePerioperative CareAnticoagulantsHeparinAnti-clotting drugHeparin bridgingLung cancer

Identifiers

PMID31848903

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.